Trial reportJournal of diabetes investigation2026
Sodium-glucose cotransporter 2 inhibition and injection burden in mild diabetic macular edema: An exploratory post hoc analysis of the COMET trial.
Trial report in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aimsTo investigate the potential of sodium-glucose cotransporter 2 inhibitors (SGLT2i) as a less invasive treatment option for mild diabetic macular edema (DMO) via post hoc subgroup analysis. Previous findings were derived exclusively from observational studies, and no interventional trials based on protocol-defined criteria had been conducted. MATERIALS AND
methodsBased on the COMET trial data, this post hoc analysis targeted mild DME cases, defined by baseline central retinal thickness (CRT) ≤375 μm and best-corrected visual acuity (BCVA) ≤0.155 (logMAR). Patients were randomized to SGLT2i (luseogliflozin) or sulfonylurea (SU, glimepiride) groups. Mild subgroups were compared with the corresponding non-mild cases. The primary outcome was the 48-week frequency of intravitreal ranibizumab injections (IVRs).
resultsIn the CRT ≤375 μm subgroup, IVR frequency was significantly lower with SGLT2i vs SU (mean 0.5 ± 1.0 vs 4.3 ± 0.8; P = 0.005, adjusted ancova. Cohen's d of 2.1). The cumulative mean number of IVRs was significantly lower in the SGLT2i group than in the SU group (P = 0.004, hazard ratio 0.29, 95% confidence interval 0.12-0.67). In the BCVA ≤ 0.155 subgroup, whose mean CRT exceeded 400 μm, no significant difference in IVR frequency was observed between the SGLT2i-treated and SU-treated patients. In addition, no intergroup differences were found in patients outside the mild subgroups.
conclusionsIn this exploratory analysis, SGLT2 inhibition was associated with fewer intravitreal injections in patients meeting the CRT-based mild criteria. These findings are hypothesis-generating and warrant confirmation in future prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.